Cargando…

B cell treatments for multiple sclerosis

Detalles Bibliográficos
Autores principales:	McLauchlan, D., Robertson, N. P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2017
Materias:	Journal Club
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5374167/ https://www.ncbi.nlm.nih.gov/pubmed/28260119 http://dx.doi.org/10.1007/s00415-017-8442-y

Ejemplares similares

Stem cells in the treatment of central nervous system disease
por: McLauchlan, Duncan, et al.
Publicado: (2018)

Reversing the trend: interventions to treat intracranial haemorrhage associated with anticoagulation
por: McLauchlan, D., et al.
Publicado: (2016)

Chronic traumatic encephalopathy: quantifying risk and clarifying pathogenesis
por: McLauchlan, D., et al.
Publicado: (2020)

Cerebral amyloid angiopathy: subtypes, treatment and role in cognitive impairment
por: McLauchlan, D., et al.
Publicado: (2017)

Stem cell treatment for multiple sclerosis
por: Owen Pickrell, W., et al.
Publicado: (2016)

Advances in the use of stem cell transplants in the treatment of multiple sclerosis
por: Thomas, Rachel, et al.
Publicado: (2022)

Multiple sclerosis: early indicators of disease and assessing future risk
por: Willis, M. D., et al.
Publicado: (2020)

Continuous evolution of magnetic resonance imaging in multiple sclerosis
por: Tallantyre, E. C., et al.
Publicado: (2016)

Innovative biomarkers to predict unfavourable outcomes after initiating multiple sclerosis treatment
por: Kreft, Karim L., et al.
Publicado: (2022)

A role for the Epstein–Barr virus in multiple sclerosis aetiology?
por: Hrastelj, J., et al.
Publicado: (2022)

Advances in biomarker research in multiple sclerosis
por: Butterworth, Sara E., et al.
Publicado: (2016)

New rare genetic variants in multiple sclerosis
por: Harding, Katharine E., et al.
Publicado: (2018)

Early MRI predictors of prognosis in multiple sclerosis
por: Davda, Nikunj, et al.
Publicado: (2019)

Multiple sclerosis and the risk of infection: considerations in the threat of the novel coronavirus, COVID-19/SARS-CoV-2
por: Willis, M. D., et al.
Publicado: (2020)

Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapies
por: Allman, M., et al.
Publicado: (2022)

Amyotrophic lateral sclerosis: an update on treatments from clinical trials
por: Wynford-Thomas, Ray, et al.
Publicado: (2023)

Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis
por: McArthur, C., et al.
Publicado: (2023)

Genetics of disease severity in multiple sclerosis, Alzheimer’s disease, and Huntington’s disease: rejuvenating genome-wide association studies
por: Hrastelj, James, et al.
Publicado: (2017)

Ice bucket challenge bears fruit for amyotrophic lateral sclerosis
por: Hrastelj, James, et al.
Publicado: (2016)

Physical activity as a risk factor for amyotrophic lateral sclerosis-findings from three large European cohorts
por: M, Hu, et al.
Publicado: (2020)

Treatments in Alzheimer’s disease
por: Malik, G. A., et al.
Publicado: (2017)

Cluster headache: an overview of established and emerging treatments
por: Al-Ansari, A., et al.
Publicado: (2019)

Autoimmune encephalitis: clinical presentation, investigation and treatment
por: Al-Ansari, A., et al.
Publicado: (2021)

Vaccine-induced immune thrombosis and thrombocytopaenia: incidence, mechanism and treatment
por: Hrastelj, J., et al.
Publicado: (2021)

Cerebral venous thrombosis: clinical predictors and emerging treatments
por: Al-Ansari, A., et al.
Publicado: (2020)

Postural orthostatic tachycardia syndrome: insights into pathogenesis and treatment
por: Al-Ansari, A., et al.
Publicado: (2021)

Preclinical retinal neurodegeneration in a model of multiple sclerosis: The Journal of Neuroscience 2012; 32(16):5585–5597
por: Mathur, Deepali, et al.
Publicado: (2012)

Treatment of progressive multifocal leukoencephalopathy
por: Castle, Daniel, et al.
Publicado: (2019)

Cannabidiol as a treatment for epilepsy
por: Pickrell, William O., et al.
Publicado: (2017)

An update on treatments in myasthenia gravis
por: Jones, Lliwen A., et al.
Publicado: (2016)

New treatments in Alzheimer’s disease
por: Pickrell, William O., et al.
Publicado: (2018)

Emerging treatments for neuromyelitis optica spectrum disorder
por: Wynford-Thomas, Ray, et al.
Publicado: (2020)

Alternatives to intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy
por: Castle, Dan, et al.
Publicado: (2019)

Idiopathic rapid eye movement sleep behaviour disorder: a potential gateway to the development of disease-modifying treatments in neurodegenerative disorders
por: Peall, K. J., et al.
Publicado: (2016)

Chronic traumatic encephalopathy: identifying those at risk and understanding pathogenesis
por: Willis, M. D., et al.
Publicado: (2017)

Myelin oligodendrocyte glycoprotein antibody-associated disease: characterising clinical disease
por: Willis, M. D., et al.
Publicado: (2018)

Neurotoxicity of novel cancer immunotherapies
por: Willis, M. D., et al.
Publicado: (2019)

MRI-guided focused ultrasound: new hope for drug-resistant neurological conditions
por: Bari, S., et al.
Publicado: (2023)

Why antisense could make sense for neurodegeneration
por: Massey, T. H., et al.
Publicado: (2017)

CGRP and migraine
por: Cauchi, M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_p68ae4tik0o0tk0mamons7fk5i